click enter text
full postview solid result boost covid
report financi result thursday open
beat revenu ep due part front-load mostli
us
guidanc larg maintain small adjust
chang model rel modest estim move
slightli higher pt target multipl increas modestli
bodi report full analysi
pipelin unplug confer call may senior
 execut dr skovronski estimate regist click
inform us/eu stock cover see
recent report global pharmaceut march issu monthli
trade fundament data
upsid target
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
thursday market open
report result higher revenu ep vs consensu us good portion
beat due front-end load
saw share price outperform drug group small margin
overal impress report good result clear boost front-load
compani made sure investor know uncertainti go forward variou front
neg payer mix certain product uncertain rate uptak brand paus clinic trial
said affirm almost element prior financi guidanc fact rais midpoint fy ep
guidanc modestli confer call analyst reflect effort teas
specif potenti neg impact deviat littl said prepar remark
apart gener lli busi continu perform well compani remain new drug launch
phase abl post higher growth peer share benefit recent flight qualiti along
certain larg cap growthier biopharma compani rais question much upsid
whether becom crowd long side term event flow event
greatest import view like releas first result tirzepatid gip/glp
amount inform may limit like top line set find also
first mani trial report total trial better defin product futur
investor expect alreadi quit high portfolio alzheim diseas asset
make deriv play rate peer perform term news flow specif
like minim advanc program apart sola trial
aducanumab look-alik top-lin result may actual come earli rate
pipelin unplug confer call may senior execut dr
skovronski estimate regist click
inform see march issu monthli controversi report
revenu higher vs consensu
non-gaap ep higher vs consensu
trulic higher consensu taltz higher vs
consensu
revenu maintain
page
non-gaap ep increas
reiter oper margin y/i expans
revenu increas slightli ep increas
revenu estim increas ep estim
increas depend year oper margin meet guidanc
ep compound-annual-growth-rate ep compound-annual-growth-rate increas well peer averag average
price target increas vs prior repres higher multipl vs
new higher ep estim multipl peer group averag reflect
compani better compar lt ep growth rate
prepar remark regard despit benefit overal expect neg effect lli
busi beyond destock fewer patient vision payer mix chang price pressur
may see impact mirikizumab time uc result otherwis expect trial timelin remain
intact clearli saw stock consum slow new therapi start boost w/w sale
us mostli across diabet insulin trulic taltz
like revers futur qs expect immunolog pain new patient start get hit
term neg payer mix neg impact lessen time economi
return normal continu invest busi keep credit rate intact volum growth
vs report expect om build throughout year hit prior fy target
share repurchas near-term inc/exp boost mtm gain
prior invest co china price saw neg impact nrdl inclus tyvyt alimta
 expand capit alloc chang say real chang apart
share repo say bd wont realli chang impact travel restrict etc smaller deal remain
focu
 price expect due say difficult predict moment mayb
modest increas beyond prior expect baselin expect singl digit price declin
page
 expect thing like unemploy might impact price gave
firm answer
 quantifi expect could step medicaid channel right
lli book us busi medicaid challeng financi would well-insur
commerci pt move medicaid expect see will quantifi
believ sale guidanc alreadi anticip tough know hold
prepar remark term lli effort find solut evalu baricitinib result june
result june ab therapi collabor abcellera near-term ind file may
 type patient focus baricitinib two potenti mechan action
may work best pt establish vs earli diseas
 would next step bari june result posit could file approv
say certainli easier bari see alreadi approv indic
could move fast yet proven moa offer bigger excit
higher po abcellera program
 expect restart major trial say mani site alreadi look term
restart suggest far away
 ct gov suggest chang clinic trial timelin occur line
comment addit context say alway time lag take
work way system
 expect normal start see wholesal normal alreadi
difficult know consum behavior would pars likelihood
 halo effect thing like drug price reform discuss suggest
benefit made addit high level remark think prior claim drug industri critic
for-profit motiv pharma wrong abat say industri need make sure behav
opportun reset public percept
 still expect result remind trial fulli enrol
proceed plan last pt visit end like see result lli tau
progress chang timelin
page
 dian-tu impact think best way target plaqu talk small
number patient trial acknowledg sola plaque-low mab gener dismiss
find smaller trial
prepar remark first tirzepatid result share later
 tirz top line complet set result say ye top line
full result
 trulic expect slowdown due say tough know lt hold month
crisi trulic held declin thing like new brand across
class show
 trulic describ like impact price remind expect low sd declin
still rang realli mayb slightli higher insulin remind
segment sale could impact make profit channel rel
neg patient mix happen
 tirzepatid talk cv event rate see thu far across develop program
acknowledg pblish paper look gip polymorph say realli like relev
program cv event rate someth would normal talk
 comment potenti shift price taltz see pretti stabl price stabl access
 chang go market strategi selpercatinib bc say chang regulatori
timelin expect action pdufa term launch think drug bring lot marketplac
market aggress even slightli differ use digit channel etc
 past seem send mix signal tyvyt one point describ us
china-onli play smaller signific still current specif develop
plan within china even importantli outsid china develop market like us/eu
say prior comment accur reflect china-onli focu coupl thing chang
nrdl also posit trial result nsclc still
focus china opportun nearer-term clear answer ex-china plan
 investor see tyvyt lung data remind posit interim
analysi show medic meet
page
exhibit show compani report actual result vs estim consensu
exhibit result vs wr estim consensu
page
exhibit summar lli financi guidanc vs estim
exhibit guidanc vs wr estim old new
page
oldnewprior wolf estimatewolf bgross marginapprox bother meffect tax rateapprox oper incom approx guidancewr estim
exhibit captur chang forecast
exhibit chang wr model
page
exhibit show incom statement product revenu summari balanc sheet/cash flow
page
incom statement incom loss cont op dilut share growth outstand
page
product revenu emgal galcanezumab anti-cgrp growth share tradjenta basaglar biosimilar share jardianc trulic women endocrinolog growth diabet alimta cyramza gastric lartruvo olaratumab verzenio abemaciclib erbitux total taltz ixekizumab olumi baricitinib jak total total earli stage factor- total
exhibit wr eli lilli balanc sheet cash flow statement
page
summari statement incom reconcil incom tax cash provid oper tax chang oper asset defer compens impair net in-process technolog net cash provid sale in-process product paid acq/loan cash provid use invest stock capit chang short term issuanc long term repay long-term cash provid use financ exchang rate cash increas decreas end balanc sheet cash equival short term properti plant goodwil current term non-curr paid-in comprehens treasuri stock sharehold liabil sharehold
